Latest revenue
$24.06B
as of 2026-03-29
Latest net income
$5.24B
as of 2026-03-29
Net margin
21.8%
as of 2026-03-29
Community sentiment
Where do you think JNJ is heading?
Keep private notes on JNJ — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
JNJ vs S&P 500 · rebased to 100
Live market
delayed ≤15 min- Market cap
- $570.59B
- Enterprise value
- $603.89B
- P/E (trailing)
- 21.3×
- Forward P/E
- —
- P/B
- 7.03×
- Dividend yield
- —
- 52-wk high
- $251.71
- 52-wk low
- $149.04
- Beta
- —
- Shares out
- 2.41B
What this company does
Johnson & Johnson develops and sells prescription pharmaceuticals and medical devices, spanning oncology, immunology, neuroscience, surgery, and orthopedics. Product sales to hospitals, providers, and distributors generate essentially all revenue, with the drug business driving the bulk of $63.8 billion in nine-month sales. The company just completed its separation of consumer-health unit Kenvue, booking a $21 billion gain and refocusing entirely on higher-margin pharmaceuticals and medtech.
Generated from JNJ's filing dated 2026-02-11
Key risks
- Talc litigation overhang: Other (income)/expense jumped to $7.1B for nine months vs $15M prior year, reflecting massive contingency charges.
- Kenvue separation removed Consumer Health: J&J shed $30B in disc-ops assets, leaving revenue concentrated in Pharma/MedTech and reducing diversification.
- Margin pressure: Continuing-ops earnings fell to $9.2B from $13.1B YoY (nine months), with operating margin halved by litigation/IPR&D charges.
Generated from JNJ's filing dated 2026-02-11
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 10, 2026.
Fair value · DCF
Methodology + caveats (click to expand)
Method. 10-year forecast of free cash flow, discounted at the company's WACC, with a Gordon-growth terminal at year 10. FCF is proxied by last fiscal-year net income (proper FCF needs CFO − CapEx by year, which we don't store yet). Beta defaults to 1.0 when not reported.
Why DCF is fragile. Treat the output as a thinking aid, not a verdict. Honest weaknesses of any DCF:
- Growth is the dominant assumption. No one can foresee 10 years of growth — small changes in the slider can double or halve fair value. The reverse-DCF readout above tells you what the market is implicitly assuming; ask yourself whether that's realistic before trusting either number.
- Terminal value dominates. In most DCFs, 60-80% of the answer comes from the terminal-value calculation — i.e., everything AFTER year 10. A 0.5pp change in terminal growth, or in WACC, can swing fair value by 20-30%.
- WACC is itself a guess. We use a textbook CAPM cost of equity (Rf 4.3%, MRP 5.5%, β from the quote) plus a 6% pretax cost of debt — none of these are the company's actual marginal financing cost.
- No moat / disruption modelling. The model assumes the company keeps earning whatever it earns today, compounding cleanly. Competitive shifts, regulatory action, and technology disruption can invalidate the forecast overnight.
- Net income ≠ free cash flow. For capex-heavy names (semis, telcos) net income overstates distributable cash. For low-capex names (software) it understates. Both reduce the precision of the FV figure.
- Reflexivity. A high stock price often becomes a self-fulfilling prophecy via better hiring, financing, and customer trust. DCF can't see this.
Take the DCF, the reverse-DCF implied growth, the historical multiples, and the community sentiment together. When they agree, conviction. When they disagree, the disagreement is the most informative thing on the page.
Historical multiples
How does JNJ's current valuation compare to its own past?
P/E uses year-end weekly close ÷ (net income ÷ shares outstanding today). Held shares constant at today's count, which understates the per-share earnings improvement from buybacks over the period. PEG uses 5y revenue CAGR as a proxy for EPS growth — close, but not identical (margin expansion or dilution can drive a wedge). Best read as a comparator across companies and industries, not as a precise replica of historical multiples.